Dianthus Therapeutics, Inc. (DNTH) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases. The company operates as a single segment and is currently advancing its lead candidate, claseprubart, alongside pipeline candidates DNTH212 and DNTH312. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| License Revenue | $761 | $193 | $1,224 | $1,356 |
| Total Operating Expenses | $62,243 | $35,120 | $109,239 | $69,460 |
| - Research & Development | $48,686 | $26,251 | $83,214 | $53,254 |
| - General & Administrative | $13,557 | $8,869 | $26,025 | $16,206 |
| Net Loss | $(50,215) | $(31,629) | $(91,049) | $(61,140) |
| Net Loss Per Share (Basic/Diluted) | $(0.90) | $(0.88) | $(1.75) | $(1.71) |
| Cash, Cash Equivalents & Investments | $1,186,813 (as of June 30, 2026) | |||
| Accumulated Deficit | $(427,778) (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue: Q2 2026 license revenue increased to $0.8 million from $0.2 million in Q2 2025, driven by higher reimbursable costs under the Tenacia License Agreement. YTD revenue decreased slightly to $1.2 million from $1.4 million due to timing of reimbursable costs.
- Operating Expenses: Total operating expenses increased significantly. R&D expenses rose $22.4 million in Q2 (to $48.7 million) and $29.9 million YTD (to $83.2 million). This was primarily due to increased clinical operations and CMC costs for claseprubart trials (gMG, CIDP, MMN) and discovery activities for DNTH212/DNTH312.
- Other Income: Interest and investment income surged to $11.5 million in Q2 2026 (from $3.4 million in Q2 2025) due to higher cash and investment balances following recent capital raises.
- Liquidity: Cash and investments grew from $404 million at year-end 2025 to $1.19 billion at June 30, 2026, following a $719 million public offering in March 2026 and a $288 million offering in September 2025.
Guidance, Outlook, and Risks
- Clinical Progress:
- Claseprubart (gMG): Initiated Phase 3 EMERGE trial in June 2026; top-line results expected H2 2028.
- Claseprubart (CIDP): Phase 3 CAPTIVATE trial achieved a 75% response rate in interim analysis (exceeding 50% target). Part B top-line guidance expected by end of 2026.
- Claseprubart (MMN): Phase 2 MoMeNtum trial enrollment completed in August 2026; results expected December 2026.
- DNTH212: Phase 1 study initiated in China (December 2025); healthy volunteer data expected by year-end 2026.
- Liquidity Outlook: Management believes existing cash, cash equivalents, and investments ($1.19 billion) are sufficient to fund operations into 2030.
- Risks: The company faces standard biotech risks including clinical trial failure, regulatory delays, and the need for future capital. Specific risks include the uncertainty of achieving milestones under the Tenacia and Leads agreements and potential dilution from future equity financings.
- Unusual Items: The company recognized $7.0 million in cumulative milestones under the Tenacia Agreements added to the transaction price as of June 30, 2026.
Investor Verification Checklist
- Verify the timeline and enrollment status of the Phase 3 CAPTIVATE (CIDP) and EMERGE (gMG) trials for claseprubart.
- Confirm the specific terms and payment schedule of the $38.0 million commitment to Nanjing Leads Biolabs for DNTH212.
- Monitor the burn rate relative to the $1.19 billion cash position to validate the "funding into 2030" projection.
- Review the status of the Tenacia License Agreement milestones and the recognition of the $7.0 million added to the transaction price.
- Assess the impact of the new Waltham, MA lease agreement (7-year term, ~$2.4 million payments) on future operating costs.